Cargando…
The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers
Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; these attributes can all affect patient compliance and therefore treatment efficacy. The ELLIPTA(®) DPI was devel...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mary Ann Liebert, Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685506/ https://www.ncbi.nlm.nih.gov/pubmed/26372466 http://dx.doi.org/10.1089/jamp.2015.1223 |
_version_ | 1782406325946286080 |
---|---|
author | Grant, Andrew C. Walker, Richard Hamilton, Melanie Garrill, Karl |
author_facet | Grant, Andrew C. Walker, Richard Hamilton, Melanie Garrill, Karl |
author_sort | Grant, Andrew C. |
collection | PubMed |
description | Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; these attributes can all affect patient compliance and therefore treatment efficacy. The ELLIPTA(®) DPI was developed for the delivery of once-daily therapies for the treatment of asthma and chronic obstructive pulmonary disease. It has moderate resistance to airflow and can hold one or two blister strips, with each blister containing a sealed single dose of medication. Monotherapies can be delivered by the single-strip configuration and, in the two-strip configuration, one dose from each strip can be aerosolized simultaneously to allow combination therapies to be delivered, which enables the formulations for each product to be developed individually, since they are stored separately until the point of administration. There are three principal operating steps to administer a dose: open, inhale, close. This article summarizes the design, functionality, and in vitro dose-delivery characteristics of the ELLIPTA inhaler, and describes the results of human factors validation tests, designed to assess the performance of critical tasks required to use the inhaler. Results from the in vitro studies indicate that the ELLIPTA inhaler performs consistently with respect to in vitro dose delivery characteristics at a range of flow rates that can be achieved by the target population (≥30 L/min) and over its 30-day in-use life. Data from the human factors validation tests demonstrated that almost all participants (≥97%) were able to complete each of the steps required to prepare a dose for inhalation without error. Overall, the ELLIPTA inhaler has a versatile single- or two-strip design that allows it to be used for the delivery of a range of treatment options. It also improves patient ease-of-use when compared with the DISKUS(®) DPI. |
format | Online Article Text |
id | pubmed-4685506 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Mary Ann Liebert, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-46855062015-12-22 The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers Grant, Andrew C. Walker, Richard Hamilton, Melanie Garrill, Karl J Aerosol Med Pulm Drug Deliv Original Research Dry powder inhalers (DPIs) are commonly used for the delivery of inhaled medications, and should provide consistent, efficient dosing, be easy to use correctly, and be liked by patients; these attributes can all affect patient compliance and therefore treatment efficacy. The ELLIPTA(®) DPI was developed for the delivery of once-daily therapies for the treatment of asthma and chronic obstructive pulmonary disease. It has moderate resistance to airflow and can hold one or two blister strips, with each blister containing a sealed single dose of medication. Monotherapies can be delivered by the single-strip configuration and, in the two-strip configuration, one dose from each strip can be aerosolized simultaneously to allow combination therapies to be delivered, which enables the formulations for each product to be developed individually, since they are stored separately until the point of administration. There are three principal operating steps to administer a dose: open, inhale, close. This article summarizes the design, functionality, and in vitro dose-delivery characteristics of the ELLIPTA inhaler, and describes the results of human factors validation tests, designed to assess the performance of critical tasks required to use the inhaler. Results from the in vitro studies indicate that the ELLIPTA inhaler performs consistently with respect to in vitro dose delivery characteristics at a range of flow rates that can be achieved by the target population (≥30 L/min) and over its 30-day in-use life. Data from the human factors validation tests demonstrated that almost all participants (≥97%) were able to complete each of the steps required to prepare a dose for inhalation without error. Overall, the ELLIPTA inhaler has a versatile single- or two-strip design that allows it to be used for the delivery of a range of treatment options. It also improves patient ease-of-use when compared with the DISKUS(®) DPI. Mary Ann Liebert, Inc. 2015-12-01 /pmc/articles/PMC4685506/ /pubmed/26372466 http://dx.doi.org/10.1089/jamp.2015.1223 Text en © The Author(s) 2015; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Research Grant, Andrew C. Walker, Richard Hamilton, Melanie Garrill, Karl The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers |
title | The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers |
title_full | The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers |
title_fullStr | The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers |
title_full_unstemmed | The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers |
title_short | The ELLIPTA(®) Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers |
title_sort | ellipta(®) dry powder inhaler: design, functionality, in vitro dosing performance and critical task compliance by patients and caregivers |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4685506/ https://www.ncbi.nlm.nih.gov/pubmed/26372466 http://dx.doi.org/10.1089/jamp.2015.1223 |
work_keys_str_mv | AT grantandrewc theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers AT walkerrichard theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers AT hamiltonmelanie theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers AT garrillkarl theelliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers AT grantandrewc elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers AT walkerrichard elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers AT hamiltonmelanie elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers AT garrillkarl elliptadrypowderinhalerdesignfunctionalityinvitrodosingperformanceandcriticaltaskcompliancebypatientsandcaregivers |